BET-ting on chromatin-based therapeutics for heart failure

Journal of Molecular and Cellular Cardiology

Volumn 74, Issue , 2014, Pages 98-102

  Haldar, Saptarsi M ^a,b   McKinsey, Timothy A ^c  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

BET proteins; Cardiac hypertrophy; Chromatin; Epigenetics; Heart failure; Transcription

Indexed keywords

ADENOSINE TRIPHOSPHATASE; BINDING PROTEIN; BRG1 PROTEIN; LYSINE; POSITIVE TRANSCRIPTION ELONGATION FACTOR B; PROTEIN BET; PROTEIN BRD2; PROTEIN BRD3; PROTEIN BRD4; PROTEIN BRDT; REGULATOR PROTEIN; UNCLASSIFIED DRUG; BCL11B PROTEIN, HUMAN; BRD4 PROTEIN, HUMAN; CARDIOTONIC AGENT; CHROMATIN; HEXIM1 PROTEIN, HUMAN; NUCLEAR PROTEIN; REPRESSOR PROTEIN; RNA BINDING PROTEIN; TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN;

CHROMATIN ASSEMBLY AND DISASSEMBLY; EPIGENETICS; GENE CONTROL; GENE EXPRESSION REGULATION; GENE PROBE; HEART VENTRICLE HYPERTROPHY; HISTONE MODIFICATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; CARDIOMEGALY; CHROMATIN; DRUG EFFECTS; GENETIC EPIGENESIS; GENETIC TRANSCRIPTION; GENETICS; HEART FAILURE; METABOLISM; PATHOLOGY;

CARDIOMEGALY; CARDIOTONIC AGENTS; CHROMATIN; EPIGENESIS, GENETIC; HEART FAILURE; HUMANS; NUCLEAR PROTEINS; POSITIVE TRANSCRIPTIONAL ELONGATION FACTOR B; REPRESSOR PROTEINS; RNA-BINDING PROTEINS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEINS;

EID: 84904736595     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2014.05.002     Document Type: Review

References (52)

1. Zhao M., Chow A., Powers J., Fajardo G., Bernstein D. Microarray analysis of gene expression after transverse aortic constriction in mice. Physiol Genomics 2004, 19:93-105.
2. Hannenhalli S., Putt M.E., Gilmore J.M., Wang J., Parmacek M.S., Epstein J.A., et al. Transcriptional genomics associates FOX transcription factors with human heart failure. Circulation 2006, 114:1269-1276.
3. van Berlo J.H., Maillet M., Molkentin J.D. Signaling effectors underlying pathologic growth and remodeling of the heart. J Clin Invest 2013, 123:37-45.
4. Lee T.I., Young R.A. Transcriptional regulation and its misregulation in disease. Cell 2013, 152:1237-1251.
5. Helin K., Dhanak D. Chromatin proteins and modifications as drug targets. Nature 2013, 502:480-488.
6. Hargreaves D.C., Crabtree G.R. ATP-dependent chromatin remodeling: genetics, genomics and mechanisms. Cell Res 2011, 21:396-420.
7. Luger K., Mader A.W., Richmond R.K., Sargent D.F., Richmond T.J. Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature 1997, 389:251-260.
8. Zhou V.W., Goren A., Bernstein B.E. Charting histone modifications and the functional organization of mammalian genomes. Nat Rev Genet 2011, 12:7-18.
9. Schreiber S.L., Bernstein B.E. Signaling network model of chromatin. Cell 2002, 111:771-778.
10. Ong C.T., Corces V.G. Enhancers: emerging roles in cell fate specification. EMBO Rep 2012, 13:423-430.
11. Spitz F., Furlong E.E. Transcription factors: from enhancer binding to developmental control. Nat Rev Genet 2012, 13:613-626.
12. Krivega I., Dean A. Enhancer and promoter interactions-long distance calls. Curr Opin Genet Dev 2012, 22:79-85.
13. Panne D. The enhanceosome. Curr Opin Struct Biol 2008, 18:236-242.
14. Goodrich J.A., Tjian R. Unexpected roles for core promoter recognition factors in cell-type-specific transcription and gene regulation. Nat Rev Genet 2010, 11:549-558.
15. Bannister A.J., Kouzarides T. Regulation of chromatin by histone modifications. Cell Res 2011, 21:381-395.
16. Rivera C.M., Ren B. Mapping human epigenomes. Cell 2013, 155:39-55.
17. Adelman K., Lis J.T. Promoter-proximal pausing of RNA polymerase II: emerging roles in metazoans. Nat Rev Genet 2012, 13:720-731.
18. Fuda N.J., Ardehali M.B., Lis J.T. Defining mechanisms that regulate RNA polymerase II transcription in vivo. Nature 2009, 461:186-192.
19. Malik S., Roeder R.G. The metazoan mediator co-activator complex as an integrative hub for transcriptional regulation. Nat Rev Genet 2010, 11:761-772.
20. Zhou Q., Li T., Price D.H. RNA polymerase II elongation control. Annu Rev Biochem 2012, 81:119-143.
21. Anand P., Brown J.D., Lin C.Y., Qi J., Zhang R., Artero P.C., et al. BET bromodomains mediate transcriptional pause release in heart failure. Cell 2013, 154:569-582.
22. Sano M., Abdellatif M., Oh H., Xie M., Bagella L., Giordano A., et al. Activation and function of cyclin T-Cdk9 (positive transcription elongation factor-b) in cardiac muscle-cell hypertrophy. Nat Med 2002, 8:1310-1317.
23. Kwak H., Fuda N.J., Core L.J., Lis J.T. Precise maps of RNA polymerase reveal how promoters direct initiation and pausing. Science 2013, 339:950-953.
24. Qu H., Fang X. A brief review on the human encyclopedia of DNA elements (ENCODE) project. Genomics Proteomics Bioinformatics 2013, 11:135-141.
25. Maurano M.T., Humbert R., Rynes E., Thurman R.E., Haugen E., Wang H., et al. Systematic localization of common disease-associated variation in regulatory DNA. Science 2012, 337:1190-1195.
26. Papait R., Cattaneo P., Kunderfranco P., Greco C., Carullo P., Guffanti A., et al. Genome-wide analysis of histone marks identifying an epigenetic signature of promoters and enhancers underlying cardiac hypertrophy. Proc Natl Acad Sci U S A 2013, 110:20164-20169.
27. Wamstad J.A., Alexander J.M., Truty R.M., Shrikumar A., Li F., Eilertson K.E., et al. Dynamic and coordinated epigenetic regulation of developmental transitions in the cardiac lineage. Cell 2012, 151:206-220.
28. Narlikar G.J., Sundaramoorthy R., Owen-Hughes T. Mechanisms and functions of ATP-dependent chromatin-remodeling enzymes. Cell 2013, 154:490-503.
29. Chang C.P., Bruneau B.G. Epigenetics and cardiovascular development. Annu Rev Physiol 2012, 74:41-68.
30. Puri P.L., Mercola M. BAF60 A, B, and Cs of muscle determination and renewal. Genes Dev 2012, 26:2673-2683.
31. Hang C.T., Yang J., Han P., Cheng H.L., Shang C., Ashley E., et al. Chromatin regulation by Brg1 underlies heart muscle development and disease. Nature 2010, 466:62-67.
32. Hu G., Schones D.E., Cui K., Ybarra R., Northrup D., Tang Q., et al. Regulation of nucleosome landscape and transcription factor targeting at tissue-specific enhancers by BRG1. Genome Res 2011, 21:1650-1658.
33. Sano M., Schneider M.D. Cyclin-dependent kinase-9: an RNAPII kinase at the nexus of cardiac growth and death cascades. Circ Res 2004, 95:867-876.
34. Michels A.A., Fraldi A., Li Q., Adamson T.E., Bonnet F., Nguyen V.T., et al. Binding of the 7SK snRNA turns the HEXIM1 protein into a P-TEFb (CDK9/cyclin T) inhibitor. EMBO J 2004, 23:2608-2619.
35. Montano M.M., Doughman Y.Q., Deng H., Chaplin L., Yang J., Wang N., et al. Mutation of the HEXIM1 gene results in defects during heart and vascular development partly through downregulation of vascular endothelial growth factor. Circ Res 2008, 102:415-422.
36. Espinoza-Derout J., Wagner M., Shahmiri K., Mascareno E., Chaqour B., Siddiqui M.A. Pivotal role of cardiac lineage protein-1 (CLP-1) in transcriptional elongation factor P-TEFb complex formation in cardiac hypertrophy. Cardiovasc Res 2007, 75:129-138.
37. Espinoza-Derout J., Wagner M., Salciccioli L., Lazar J.M., Bhaduri S., Mascareno E., et al. Positive transcription elongation factor b activity in compensatory myocardial hypertrophy is regulated by cardiac lineage protein-1. Circ Res 2009, 104:1347-1354.
38. Mascareno E., Galatioto J., Rozenberg I., Salciccioli L., Kamran H., Lazar J.M., et al. Cardiac lineage protein-1 (CLP-1) regulates cardiac remodeling via transcriptional modulation of diverse hypertrophic and fibrotic responses and angiotensin II-transforming growth factor beta (TGF-beta1) signaling axis. J Biol Chem 2012, 287:13084-13093.
39. Yoshikawa N., Shimizu N., Maruyama T., Sano M., Matsuhashi T., Fukuda K., et al. Cardiomyocyte-specific overexpression of HEXIM1 prevents right ventricular hypertrophy in hypoxia-induced pulmonary hypertension in mice. PLoS One 2012, 7:e52522.
40. Montano M.M., Desjardins C.L., Doughman Y.Q., Hsieh Y.H., Hu Y., Bensinger H.M., et al. Inducible re-expression of HEXIM1 causes physiological cardiac hypertrophy in the adult mouse. Cardiovasc Res 2013, 99:74-82.
41. Cherrier T., Le D.V., Eilebrecht S., Riclet R., Marban C., Dequiedt F., et al. CTIP2 is a negative regulator of P-TEFb. Proc Natl Acad Sci U S A 2013, 110:12655-12660.
42. Spiltoir J.I., Stratton M.S., Cavasin M.A., Demos-Davies K., Reid B.G., Qi J., et al. BET acetyl-lysine binding proteins control pathological cardiac hypertrophy. J Mol Cell Cardiol 2013, 63:175-179.
43. Bisgrove D.A., Mahmoudi T., Henklein P., Verdin E. Conserved P-TEFb-interacting domain of BRD4 inhibits HIV transcription. Proc Natl Acad Sci U S A 2007, 104:13690-13695.
44. Jang M.K., Mochizuki K., Zhou M., Jeong H.S., Brady J.N., Ozato K. The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription. Mol Cell 2005, 19:523-534.
45. Yang Z., Yik J.H., Chen R., He N., Jang M.K., Ozato K., et al. Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. Mol Cell 2005, 19:535-545.
46. Houzelstein D., Bullock S.L., Lynch D.E., Grigorieva E.F., Wilson V.A., Beddington R.S. Growth and early postimplantation defects in mice deficient for the bromodomain-containing protein Brd4. Mol Cell Biol 2002, 22:3794-3802.
47. Filippakopoulos P., Qi J., Picaud S., Shen Y., Smith W.B., Fedorov O., et al. Selective inhibition of BET bromodomains. Nature 2010, 468:1067-1073.
48. Grueter C.E., van R.E., Johnson B.A., DeLeon S.M., Sutherland L.B., Qi X., et al. A cardiac microRNA governs systemic energy homeostasis by regulation of MED13. Cell 2012, 49:671-683.
49. Pan H., Qin K., Guo Z., Ma Y., April C., Gao X., et al. Negative elongation factor controls energy homeostasis in cardiomyocytes. Cell Rep 2014; Apr 10, 7(1):79-85. Epub 2014 Mar 20. PMID 24656816.
50. McKinsey T.A. Therapeutic potential for HDAC inhibitors in the heart. Annu Rev Pharmacol Toxicol 2012, 52:303-319.
51. Balder J.W., Staels B., Kuivenhoven J.A. Pharmacological interventions in human HDL metabolism. Curr Opin Lipidol 2013, 24:500-509.
52. Wee S., Dhanak D., Li H., Armstrong S.A., Copeland R.A., Sims R., et al. Targeting epigenetic regulators for cancer therapy. Ann N Y Acad Sci 2014, 1309:30-36.